FILED PURSUANT TO RULE 424(B)(5)
REGISTRATION NO. 333-138395
PROSPECTUS SUPPLEMENT
(TO PROSPECTUS DATED NOVEMBER 3, 2006)
20,000,000 SHARES
[LOGO OMITTED]
CELGENE CORPORATION
COMMON STOCK
------------------
We are offering 20,000,000 shares of common stock to be sold in this
offering.
Our common stock is traded on the NASDAQ Global Select Market under the
symbol "CELG." On November 3, 2006, the last reported sale price for our common
stock on the NASDAQ Global Select Market was $51.65 per share.
INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE "RISK FACTORS" ON PAGE
S-5.
------------------
PER SHARE TOTAL
--------- -----
Public offering price .................... $51.60 $1,032,000,000
Underwriting discount .................... $ 1.26 $ 25,200,000
Proceeds, before expenses, to us ......... $50.34 $1,006,800,000
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this
prospectus supplement or the accompanying prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.
The underwriters expect to deliver the shares against payment in New
York, New York on November 9, 2006.
------------------
JOINT BOOK-RUNNING MANAGERS
JPMORGAN MERRILL LYNCH & CO.
JOINT LEAD MANAGERS
BEAR, STEARNS & CO. INC.
CITIGROUP
GOLDMAN, SACHS & CO.
MORGAN STANLEY
CO-MANAGERS
FRIEDMAN BILLINGS RAMSEY
JMP SECURITIES
LAZARD CAPITAL MARKETS
LEERINK SWANN & COMPANY
PIPER JAFFRAY
RODMAN & RENSHAW
THOMAS WEISEL PARTNERS LLC
------------------
The date of this prospectus supplement is November 3, 2006
TABLE OF CONTENTS
PROSPECTUS SUPPLEMENT
PAGE
----
About this Prospectus Supplement .......................................... S-1
Summary ................................................................... S-2
The Offering .............................................................. S-4
Risk Factors .............................................................. S-5
Forward-Looking Statements ................................................ S-6
Use of Proceeds ........................................................... S-7
Description of Capital Stock .............................................. S-8
Underwriting ..............................................................S-10
Legal Matters .............................................................S-12
Where You Can Find More Information .......................................S-12
Incorporation by Reference ................................................S-13
PROSPECTUS
About this Prospectus ..................................................... 1
Prospectus Summary ........................................................ 2
Risk Factors .............................................................. 3
Forward-Looking Statements ................................................ 3
Use of Proceeds ........................................................... 4
Ratio of Earnings to Fixed Charges ........................................ 5
Description of Capital Stock .............................................. 6
Description of Debt Securities ............................................ 7
Plan of Distribution ...................................................... 15
Legal Matters ............................................................. 16
Experts ................................................................... 16
Where You Can Find More Information ....................................... 17
Incorporation by Reference ................................................ 18
------------------------
YOU SHOULD RELY ONLY ON THE INFORMATION IN THIS PROSPECTUS SUPPLEMENT, THE
ACCOMPANYING PROSPECTUS AND THE DOCUMENTS INCORPORATED BY REFERENCE. NEITHER WE
NOR THE UNDERWRITERS HAVE AUTHORIZED ANYONE TO PROVIDE YOU WITH ADDITIONAL OR
DIFFERENT INFORMATION. THE INFORMATION IN THESE DOCUMENTS IS ACCURATE ONLY AS OF
THEIR RESPECTIVE DATES, REGARDLESS OF THE TIME OF DELIVERY OF ANY DOCUMENT OR OF
ANY SALE OF COMMON STOCK. OUR BUSINESS, FINANCIAL CONDITION, RESULTS OF
OPERATIONS AND PROSPECTS MAY HAVE CHANGED SINCE THE DATE ON ANY DOCUMENT. WE ARE
MAKING OFFERS TO SELL AND SEEKING OFFERS TO BUY SHARES OF COMMON STOCK ONLY IN
JURISDICTIONS WHERE OFFERS AND SALES ARE PERMITTED. YOU SHOULD NOT CONSIDER THIS
PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS TO BE AN OFFER TO SELL, OR
A SOLICITATION OF AN OFFER TO BUY, SHARES OF COMMON STOCK IF THE PERSON MAKING
THE OFFER OR SOLICITATION IS NOT QUALIFIED TO DO SO OR IF IT IS UNLAWFUL FOR YOU
TO RECEIVE THE OFFER OR SOLICITATION.
ABOUT THIS PROSPECTUS SUPPLEMENT
In this prospectus supplement and the accompanying prospectus, unless
otherwise indicated, the terms "Celgene," "we," "us" and "our" refer and relate
to Celgene Corporation and its consolidated subsidiaries.
This document is in two parts. The first part is this prospectus
supplement, which describes the terms of the offering and also adds to and
updates information contained in the accompanying prospectus. The second part is
the accompanying prospectus, which provides more general information. To the
extent there is a conflict between the information contained in this prospectus
supplement, on the one hand, and the information contained in the accompanying
prospectus or in the previously filed documents incorporated by reference, on
the other hand, you should rely on the information in this prospectus
supplement. It is also important for you to read and consider all information
contained in this prospectus supplement and the accompanying prospectus,
including the documents we have referred you to in the section entitled "Where
You Can Find More Information" below in this prospectus supplement. The
information incorporated by reference is considered part of this prospectus
supplement, and information we file later with the Securities and Exchange
Commission, or SEC, may automatically update and supersede this information.
S-1
SUMMARY
THIS SUMMARY HIGHLIGHTS INFORMATION CONTAINED IN THE DOCUMENTS INCORPORATED
BY REFERENCE. THIS SUMMARY DOES NOT CONTAIN ALL OF THE INFORMATION THAT YOU
SHOULD CONSIDER BEFORE DECIDING TO INVEST IN OUR COMMON STOCK. YOU SHOULD READ
THIS ENTIRE PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS CAREFULLY,
INCLUDING THE "RISK FACTORS" SECTION BEGINNING ON PAGE S-5 OF THIS PROSPECTUS
SUPPLEMENT, THE RISKS OF AN INVESTMENT IN OUR COMPANY SET FORTH UNDER THE
CAPTIONS "ITEM 1A. RISK FACTORS" AND "ITEM 7. MANAGEMENT'S DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION" IN OUR ANNUAL REPORT
ON FORM 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2005 (AS UPDATED BY OUR
CURRENT REPORT ON FORM 8-K DATED NOVEMBER 3, 2006), AND OUR CONSOLIDATED
FINANCIAL STATEMENTS AND THE RELATED NOTES AND THE OTHER INFORMATION
INCORPORATED BY REFERENCE INTO THIS PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING
PROSPECTUS BEFORE MAKING AN INVESTMENT DECISION.
CELGENE CORPORATION
We are a multi-national biopharmaceutical company primarily engaged in the
discovery, development and commercialization of innovative therapies designed to
treat cancer and immune-inflammatory related diseases. Our primary commercial
products are: REVLIMID(R) (lenalidomide), which was approved by the U.S. Food
and Drug Administration, or FDA, in December 2005 for treatment of patients with
transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic
syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or
without additional cytogenetic abnormalities and in June 2006 for treatment in
combination with dexamethasone for multiple myeloma patients who have received
at least one prior therapy; and THALOMID(R) (thalidomide), which gained FDA
approval in May 2006 for treatment in combination with dexamethasone of newly
diagnosed multiple myeloma patients and which is also approved in erythema
nodosum leprosum, an inflammatory complication of leprosy. The sales growth of
REVLIMID(R) and THALOMID(R) has enabled us to make substantial investments in
research and development, which has advanced our broad portfolio of drug
candidates in our product pipeline, including a pipeline of IMiD(R) compounds,
which are proprietary to us and have demonstrated certain anti-proliferative
immunomodulatory and other biologically important properties. We believe that
the commercial potential of REVLIMID(R) and THALOMID(R), the depth of our
product pipeline, near-term regulatory activities, new disease indications,
geographic/international market expansion and clinical data reported both at
major medical conferences and in peer-reviewed publications provide the
catalysts for future growth.
We are dedicated to innovative research and development designed to bring
new therapies to market. We are involved in research in several scientific areas
that may deliver proprietary next-generation therapies, such as cellular
signaling biology, immunomodulation and placental stem cell research. The
therapies (drugs and cell therapies) we develop are designed to treat
life-threatening diseases or chronic debilitating conditions where patients are
poorly served by current therapies. Building on our growing knowledge of the
biology underlying hematological and solid tumor cancers and immune-inflammatory
diseases, we are investing in a range of innovative therapeutic programs that
are investigating ways to target or treat chronically managed diseases by
targeting multiple mechanisms at their source.
Our principal executive offices are located at 86 Morris Avenue, Summit,
New Jersey 07901, and our telephone number is (908) 673-9000. Additional
information regarding us is set forth in our Annual Report on Form 10-K for the
fiscal year ended December 31, 2005, our Quarterly Reports on Form 10-Q for the
fiscal quarters ended March 31, 2006 and June 30, 2006 and our Current Reports
on Form 8-K filed with the SEC (which are incorporated by reference in this
prospectus supplement and the accompanying prospectus). See "Where You Can Find
More Information" and "Incorporation by Reference."
RECENT EVENTS
Celgene reported net income of $20.4 million, or diluted earnings per share
of $0.05 for the quarter ended September 30, 2006, including share-based
employee compensation expense, compared to net income in the prior year period
of $0.7 million, or diluted earnings per share of $0.00. Total revenue was
$244.8 million for the quarter ended September 30, 2006, an increase of 89.1%
over the same period in 2005 driven by REVLIMID(R) net sales of
S-2
$101.3 million, aided by conversion of expanded access patients to paying
patients and $5 million to $10 million of inventory build related to the
introduction of the new 15 and 25 milligram capsules and THALOMID(R) net sales
were $108.4 million, an increase of 9.3% year-over-year. ALKERAN(R) net sales
for the third quarter were $12.2 million in 2006 compared to $13.9 million in
2005. Revenue from FocalinTM and the Ritalin(R) family of drugs totaled $17.9
million for the third quarter of 2006 compared to $10.7 million over the same
period last year.
For the nine-month period, total net product sales were $559.7 million, an
increase of 76.6% over the same period in 2005. REVLIMID(R) sales for the
nine-month period were $196.8 million. THALOMID(R) sales for the nine-month
period of 2006 were $322.8 million compared to $282.0 million in 2005, an
increase of 14.5% year-over-year. During the nine-month period of 2006, Celgene
announced net income of $46.1 million or earnings per diluted share of $0.12,
compared to net income of $59.7 million or earnings of $0.16 per diluted share
in the first nine months of last year.
Selling, general and administrative expenses were $89.6 million for the
three-month period ended September 30, 2006, representing an increase of 90.9%
compared to the year ago quarter. Selling, general and administrative expenses
during the third quarter of 2006 included $20.1 million of share-based
compensation expense resulting from the application of Statement of Financial
Accounting Standards No. 123(R), "Share-Based Payment," effective January 1,
2006. Selling, general and administrative expenses also increased due to higher
marketing and sales expenses related to REVLIMID(R) and THALOMID(R) product
launch activities in the United States, and continued expansion of Celgene
internationally.
Celgene reported $872.5 million in cash and marketable securities as of
September 30, 2006, an increase of $148.2 million from December 31, 2005.
S-3
THE OFFERING
Common stock offered by us
in this offering ................... 20,000,000 shares
Common stock to be outstanding
after this offering ................ 372,441,666 shares (based upon
352,441,666 shares of common stock
outstanding as of November 1, 2006)
Offering price of common stock
in this offering ................... $51.60 per share
Use of Proceeds ...................... We intend to use the net proceeds of this
offering for general corporate purposes,
including, without limitation, further
development of our clinical and
pre-clinical programs, expansion of our
international operations, capital
expenditures, repayment of indebtedness
and to meet working capital needs. We
expect from time to time to evaluate the
acquisition of businesses, products and
technologies for which a portion of the
net proceeds may be used.
Risk Factors ......................... Investing in our securities involves
risks. See "Risk Factors" on page S-5.
Nasdaq Global Select
Market Symbol ...................... CELG
Transfer Agent ....................... American Stock Transfer & Trust Company
The number of shares of our common stock to be outstanding after this
offering is based on shares of common stock outstanding as of November 1, 2006
and does not include:
o 40,585,992 shares of our common stock issuable upon exercise of stock
options outstanding under our stock option plans as of September 30,
2006, at a weighted average exercise price of $16.9288;
o 22,696,267 shares of our common stock available as of September 30, 2006
for future grant or issuance pursuant to our stock option plans;
o 378,652 shares of our common stock issuable upon exercise of outstanding
warrants as of September 30, 2006, at a weighted average exercise price
of $2.94324; and
o 33,020,545 shares of our common stock issuable upon conversion of our
unsecured convertible notes as of September 30, 2006 at a conversion
price of $12.1125.
S-4
RISK FACTORS
Investment in the offered securities involves risks. Before acquiring any
offered securities pursuant to this prospectus supplement and the accompanying
prospectus, you should carefully consider the information contained or
incorporated by reference in this prospectus supplement or in the accompanying
prospectus, including, without limitation, the risks of an investment in our
company set forth under the captions "Item 1A. Risk Factors" and "Item 7.
Management's Discussion and Analysis of Financial Condition and Results of
Operations" in our Annual Report on Form 10-K for the fiscal year ended December
31, 2005 (as updated by our Current Report on Form 8-K dated
November 3, 2006), Item 2. "Management's Discussion and Analysis of Financial
Condition and Results of Operations" in our Quarterly Reports for the fiscal
quarters ended March 31, 2006 and June 30, 2006 and our Current Reports on Form
8-K, as the same may be updated from time to time by our future filings with the
SEC. The occurrence of any of these risks might cause you to lose all or a part
of your investment in the offered securities. Please also refer to the section
entitled "Forward-Looking Statements."
WE MAY APPLY THE PROCEEDS OF THIS OFFERING TO USES THAT DO NOT IMPROVE OUR
OPERATING RESULTS OR INCREASE THE VALUE OF YOUR INVESTMENT.
We anticipate that we will use the net proceeds from this offering for
general corporate purposes, including working capital and capital expenditures.
In addition, we may use proceeds of this offering for acquisitions of
businesses, technologies or other assets that we believe will complement our
business. Pending such uses, we may be limited in the types of investments we
can make with the proceeds in order to comply with the requirements of the
Investment Company Act of 1940. As a result of the foregoing, these proceeds
could be applied in ways that do not improve our operating results or increase
the value of your investment.
S-5
FORWARD-LOOKING STATEMENTS
Certain statements contained or incorporated by reference in this
prospectus supplement and the accompanying prospectus are forward-looking
statements within the meaning of Section 27A of the Securities Act and Section
21E of the Securities Exchange Act of 1934 (the "Exchange Act") and are
included, for example, in the discussions about:
o our strategy;
o new product discovery, development or product introduction;
o product manufacturing;
o product sales, royalties and contract revenues;
o expenses and net income;
o investment income;
o capital investments;
o clinical and regulatory activities;
o our credit risk management;
o our liquidity;
o our asset/liability risk management; and
o our operational and legal risks.
These and other forward-looking statements involve risks and uncertainties.
Actual results may differ materially from those expressed or implied in those
statements. You are cautioned not to unduly rely on the forward-looking
statements contained in this prospectus supplement and the accompanying
prospectus. Factors that could cause such differences include, but are not
limited to, those risks and uncertainties discussed under the caption "Item 1A.
Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2005, Part 1, Item 2. "Management's Discussion and Analysis of
Financial Condition and Results of Operations" in our Quarterly Reports for the
fiscal quarters ended March 31, 2006 and June 30, 2006 and our Current Reports
on Form 8-K that are incorporated by reference in this prospectus supplement.
S-6
USE OF PROCEEDS
We intend to use the net proceeds of this offering for general corporate
purposes, including, without limitation, further development of our clinical and
pre-clinical programs, expansion of our international operations, capital
expenditures, repayment of indebtedness and to meet working capital needs. We
expect from time to time to evaluate the acquisition of businesses, products and
technologies for which a portion of the net proceeds may be used.
S-7
DESCRIPTION OF CAPITAL STOCK
Our authorized capital stock consists of 575,000,000 shares of common
stock, par value $.01 per share, and 5,000,000 shares of preferred stock, par
value $.01 per share, of which 520 shares have been designated Series A
convertible preferred stock and 20,000 shares have been designated as Series B
convertible preferred stock. As of November 1, 2006, there were 352,441,666
shares of common stock outstanding, no shares of Series A convertible preferred
stock outstanding and no shares of Series B convertible preferred stock
outstanding.
COMMON STOCK
Holders of common stock are entitled to one vote for each share held on all
matters submitted to a vote of stockholders, and do not have cumulative voting
rights. Holders of common stock are entitled to receive ratably such dividends,
if any, as may be declared by our board of directors out of funds legally
available therefor, and subject to any preferential dividend rights of any then
outstanding preferred stock. Upon our liquidation, dissolution or winding up,
the holders of common stock are entitled to receive ratably our net assets
available after the payment of all debts and other liabilities and subject to
any liquidation preference of any then outstanding preferred stock. Holders of
common stock have no preemptive, subscription or conversion rights. There are no
redemption or sinking fund provisions applicable to the common stock. The
outstanding shares of common stock are, and any shares offered by us in this
offering will be when issued and paid for, fully paid and non-assessable.
PREFERRED STOCK
Our board of directors has the authority, subject to certain restrictions,
without further stockholder approval, to issue, at any time and from time to
time, shares of preferred stock in one or more series. Each such series shall
have such number of shares, designations, preferences, voting powers,
qualifications and special or relative rights or privileges as shall be
determined by our board of directors, which may include, among others, dividend
rights, voting rights, redemption and sinking fund provisions, liquidation
preferences, conversion rights and preemptive rights, to the full extent now or
hereafter permitted by the laws of the State of Delaware.
The rights of the holders of common stock will be subject to, and may be
adversely affected by, the rights of holders of any preferred stock that may be
issued in the future. Such rights may include voting and conversion rights which
could adversely affect the holders of the common stock. Satisfaction of any
dividend or liquidation preferences of outstanding preferred stock would reduce
the amount of funds available, if any, for the payment of dividends or
liquidation amounts on common stock. Holders of preferred stock would typically
be entitled to receive a preference payment.
SHAREHOLDER RIGHTS PLAN
Our board of directors has adopted a shareholder rights plan. The
shareholder rights plan was adopted to give our board of directors increased
power to negotiate in our best interests and to discourage appropriation of
control of us at a price that is unfair to our stockholders. It is not intended
to prevent fair offers for acquisition of control determined by our board of
directors to be in the best interests of us and our stockholders, nor is it
intended to prevent a person or group from obtaining representation on or
control of our board of directors through a proxy contest, or to relieve our
board of directors of its fiduciary duty to consider any proposal for our
acquisition in made good faith.
The shareholder rights plan involves the distribution of one "right" as a
dividend on each outstanding share of our common stock to all holders of record
on September 26, 1996, and an ongoing distribution of one right with respect to
each share of our common stock issued subsequently. Each right shall entitle the
holder to purchase one-tenth of a share of common stock. The rights trade in
tandem with the common stock until, and become exercisable upon, the occurrence
of certain triggering events, and the exercise price is based on the estimated
long-term value of our common stock. The exercise of these rights becomes
economically attractive upon the triggering of certain "flip-in" or "flip-over"
rights which work in conjunction with the shareholder rights plan's basic
provisions. The flip-in rights will permit their holders to purchase shares of
common stock at a discounted rate, resulting in substantial dilution of an
acquiror's voting and economic interests in us. The flip-over element of the
shareholder rights plan involves some mergers or significant asset purchases,
which trigger certain rights to purchase shares of
S-8
the acquiring or surviving company at a discount. The shareholder rights plan
contains a "permitted offer" exception which allows offers determined by our
board of directors to be in our best interests and our stockholders to take
place free of the diluting effects of the shareholder rights plan's mechanisms.
Our board of directors retains the right, at all times prior to acquisition
of 15% or more of our voting common stock by an acquiror, to discontinue the
shareholder rights plan through the redemption of all rights, or to amend the
shareholder rights plan in any respect. In February 2000, we amended the
shareholder rights plan to increase the initial exercise price thereunder from
$100 to $700. In August 2003, we amended the shareholder rights plan to provide
that a qualified institutional investor (as defined in the amendment) will not
trigger any rights under the plan until it beneficially owns at least 17% of the
shares of our outstanding common stock, rather than 15%.
DELAWARE LAW AND SOME BY-LAW PROVISIONS
Our board of directors has adopted certain amendments to our by-laws
intended to strengthen our board of directors' position in the event of a
hostile takeover attempt. These by-law provisions have the following effects:
o they provide that only persons who are nominated in accordance with the
procedures set forth in the by-laws shall be eligible for election as
our directors, except as may be otherwise provided in the by-laws;
o they provide that only business brought before the annual meeting by our
board of directors or by a stockholder who complies with the procedures
set forth in the by-laws may be transacted at an annual meeting of
stockholders;
o they provide that only the chairman of the board, if any, the chief
executive officer, the president, the secretary or a majority of our
board of directors may call special meetings of our stockholders;
o they establish a procedure for our board of directors to fix the record
date whenever stockholder action by written consent is undertaken; and
o they require a vote of holders of two-thirds of the outstanding shares
of common stock to amend certain by-law provisions.
Furthermore, we are subject to the provisions of Section 203 of the
Delaware General Corporation Law, an anti-takeover law. In general, the statute
prohibits a publicly held Delaware corporation from engaging in a "business
combination" with an "interested stockholder" for a period of three years after
the date of the transaction in which the person became an interested
stockholder, unless the business combination is approved in a prescribed manner.
For purposes of Section 203, a "business combination" includes a merger, asset
sale or other transaction resulting in a financial benefit to the interested
stockholder, and an "interested stockholder" is a person who, together with
affiliates and associates, owns, or within three years prior, did own, 15% or
more of the corporation's voting stock.
TRANSFER AGENT AND REGISTRAR
The transfer agent and registrar for the common stock is American Stock
Transfer & Trust Company. It is located at 59 Maiden Lane, New York, NY 10038,
and its telephone number is (718) 921-8200.
S-9
UNDERWRITING
We intend to offer the shares through the underwriters. J.P. Morgan
Securities Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated are
acting as representatives of the underwriters named below. Subject to the terms
and conditions described in a purchase agreement among us and the underwriters,
the underwriters severally have agreed to purchase from us the number of shares
listed opposite their names below.
NUMBER
UNDERWRITER OF SHARES
----------- ---------
J.P. Morgan Securities Inc. .................................. 5,072,000
Merrill Lynch, Pierce, Fenner & Smith
Incorporated ..................................... 5,072,000
Bear, Stearns & Co. Inc. ..................................... 1,792,000
Citigroup Global Markets Inc. ................................ 1,792,000
Goldman, Sachs & Co. ......................................... 1,792,000
Morgan Stanley & Co. Incorporated ............................ 1,792,000
Friedman, Billings, Ramsey & Co., Inc. ....................... 384,000
JMP Securities LLC ........................................... 384,000
Lazard Capital Markets LLC ................................... 384,000
Leerink Swann & Company ...................................... 384,000
Piper Jaffray & Co. .......................................... 384,000
Rodman & Renshaw, LLC ........................................ 384,000
Thomas Weisel Partners LLC ................................... 384,000
-----------
Total ............................................ 20,000,000
===========
The underwriters have agreed to purchase all of the shares sold under the
purchase agreement if any of these shares are purchased. If an underwriter
defaults, the purchase agreement provides that the purchase commitments of the
nondefaulting underwriters may be increased or the purchase agreement may be
terminated.
We have agreed to indemnify the underwriters against certain liabilities,
including liabilities under the Securities Act of 1933, as amended, or to
contribute to payments the underwriters may be required to make in respect of
those liabilities.
The underwriters are offering the shares, subject to prior sale, when, as
and if issued to and accepted by them, subject to approval of legal matters by
their counsel, including the validity of the shares, and other conditions
contained in the purchase agreement, such as the receipt by the underwriters of
officer's certificates and legal opinions. The underwriters reserve the right to
withdraw, cancel or modify offers to the public and to reject orders in whole or
in part.
COMMISSIONS AND DISCOUNTS
The representatives have advised us that the underwriters propose initially
to offer the shares to the public at the public offering price on the cover page
of this prospectus supplement and to dealers at that price less a concession not
in excess of $0.75 per share. After the public offering, the public offering
price, concession and discount may be changed.
The following table shows the public offering price, underwriting discount
and proceeds before expenses to us.
PER SHARE TOTAL
--------- --------------
Public offering price ....................... $51.60 $1,032,000,000
Underwriting discount ....................... $ 1.26 $ 25,200,000
Proceeds, before expenses, to us ............ $50.34 $1,006,800,000
S-10
The expenses of the offering, not including the underwriting discount, are
estimated at $650,000 and are payable by us.
QUOTATION ON THE NASDAQ GLOBAL SELECT MARKET
The shares are quoted on the Nasdaq Global Select Market under the symbol
"CELG."
PRICE STABILIZATION, SHORT POSITIONS
Until the distribution of the shares is completed, SEC rules may limit
underwriters and selling group members from bidding for and purchasing our
common stock. However, the representatives may engage in transactions that
stabilize the price of the common stock, such as bids or purchases to peg, fix
or maintain that price.
If the underwriters create a short position in the common stock in
connection with the offering, i.e., if they sell more shares than are listed on
the cover of this prospectus supplement, the representatives may reduce that
short position by purchasing shares in the open market. Purchases of the common
stock to stabilize its price or to reduce a short position may cause the price
of the common stock to be higher than it might be in the absence of such
purchases.
Neither we nor any of the underwriters makes any representation or
prediction as to the direction or magnitude of any effect that the transactions
described above may have on the price of the common stock. In addition, neither
we nor any of the underwriters makes any representation that the representatives
will engage in these transactions or that these transactions, once commenced,
will not be discontinued without notice.
PASSIVE MARKET MAKING
In connection with this offering, underwriters and selling group members
may engage in passive market making transactions in the common stock on the
Nasdaq Global Select Market in accordance with Rule 103 of Regulation M under
the Exchange Act during a period before the commencement of offers or sales of
common stock and extending through the completion of distribution. A passive
market maker must display its bid at a price not in excess of the highest
independent bid of that security. However, if all independent bids are lowered
below the passive market maker's bid, that bid must then be lowered when
specified purchase limits are exceeded.
INTERNET DISTRIBUTION
Merrill Lynch may facilitate internet distribution for this offering to
certain of its internet subscription customers. Merrill Lynch may allocate a
limited number of shares for sale to its online brokerage customers. An
electronic prospectus supplement is available on the internet website
maintained by Merrill Lynch. Other than the prospectus supplement in electronic
format, the information on the Merrill Lynch website is not part of this
prospectus supplement.
In addition, a prospectus supplement in electronic format may be made
available on the website maintained by JPMorgan and may also be made available
on websites maintained by other underwriters. The underwriters may agree to
allocate a number of shares to underwriters for sale to their online brokerage
account holders. Internet distributions will be allocated by the lead managers
to underwriters that may make internet distributions on the same basis as other
allocations.
OTHER RELATIONSHIPS
Certain of the underwriters and their respective affiliates have, from time
to time, performed, and may in the future perform, various financial advisory
and investment banking services for us, for which they received or will receive
customary fees and expenses.
S-11
LEGAL MATTERS
Proskauer Rose LLP, New York, New York, will pass upon the validity of the
issuance of the common stock offered by this prospectus supplement. Certain
legal matters relating to this offering will be passed upon for the underwriters
by Fried, Frank, Harris, Shriver & Jacobson LLP, New York, New York.
WHERE YOU CAN FIND MORE INFORMATION
We are required to file annual, quarterly and current reports, proxy
statements and other information with the SEC. You may read and copy any
document that we file with the SEC at the SEC's Public Reference Room at 100 F
Street, N.E., Washington, D.C. 20549. You may obtain information about the
Public Reference Room by calling the SEC for more information at 1-800-SEC-0330.
Our SEC filings are also available at the SEC's web site at http://www.sec.gov.
Our common stock is listed on the NASDAQ Global Select Market under the
symbol "CELG" and we are required to file reports, proxy statements and other
information with NASDAQ. You may read any document we file with NASDAQ at the
offices of the NASDAQ Stock Market, Inc. For further information about obtaining
copies of our public filings from the NASDAQ Global Select Market, please call
(212) 401-8700.
S-12
INCORPORATION BY REFERENCE
The SEC's rules allow us to "incorporate by reference" the information we
file with them, which means that we can disclose important information to you by
referring you to those documents. The information incorporated by reference is
considered to be part of this prospectus supplement, and information that we
file later with the SEC will automatically update and, where applicable,
supersede any information.
We incorporate by reference into this prospectus supplement the following
documents or information filed with the SEC (other than, in each case, documents
or information deemed to have been furnished and not filed in accordance with
SEC rules):
1. Our Annual Report on Form 10-K for the fiscal year ended December 31,
2005 (as updated by our Current Report on Form 8-K dated November 3,
2006);
2. Our Quarterly Reports on Form 10-Q for fiscal quarters ended March 31,
2006 and June 30, 2006;
3. Our Current Reports on Form 8-K filed with the SEC on January 3, 2006,
January 20, 2006, February 21, 2006, April 20, 2006, May 3, 2006, May
26, 2006, June 23, 2006, June 30, 2006 and November 3, 2006.
4. The description of our common stock contained in our Registration
Statement on Form 8-A, File No. 0-16132, including any amendment or
report filed for the purpose of updating such description;
5. All documents filed by us with the SEC pursuant to Sections 13(a),
13(c), 14 or 15(d) of the Exchange Act on or after the date of this
prospectus supplement and prior to the termination of the offering.
You may request a copy of these filings, at no cost, by writing or
telephoning our Secretary at the following address:
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
(908) 673-9000
S-13
PROSPECTUS
CELGENE CORPORATION
COMMON STOCK
SENIOR DEBT SECURITIES
SUBORDINATED DEBT SECURITIES
-------------------
Celgene Corporation may offer to sell from time to time common stock and senior
or subordinated debt securities separately or together. The debt securities may
be convertible into or exercisable or exchangeable for our common stock. In
addition, this prospectus may be used to offer securities for the account of
persons other than us.
This prospectus describes some of the general terms that may apply to the
offered securities. The specific terms and amounts of the offered securities
will be fully described in supplements to this prospectus. Please read any
prospectus supplements and this prospectus carefully before you invest.
-------------------
Our common stock is traded on the NASDAQ Global Select Market under the symbol
"CELG." On November 2, 2006, the last reported sale price for our common stock
on the NASDAQ Global Select Market was $51.08 per share.
-------------------
INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE "RISK FACTORS" ON PAGE 3.
-------------------
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS
PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
-------------------
We or any selling security holder may offer and sell these securities to or
through one or more underwriters, dealers and agents, or directly to purchasers,
on a continuous or delayed basis.
Prospectus dated November 3, 2006
TABLE OF CONTENTS
PAGE
ABOUT THIS PROSPECTUS................................................1
PROSPECTUS SUMMARY...................................................2
RISK FACTORS.........................................................3
FORWARD-LOOKING STATEMENTS...........................................3
USE OF PROCEEDS......................................................4
RATIO OF EARNINGS TO FIXED CHARGES...................................5
DESCRIPTION OF CAPITAL STOCK.........................................6
DESCRIPTION OF DEBT SECURITIES.......................................8
PLAN OF DISTRIBUTION.................................................16
LEGAL MATTERS........................................................16
EXPERTS..............................................................16
WHERE YOU CAN FIND MORE INFORMATION..................................17
INCORPORATION BY REFERENCE...........................................18
------------------------
ABOUT THIS PROSPECTUS
We have filed with the Securities and Exchange Commission, or the SEC, a "shelf"
registration statement on Form S-3 under the Securities Act of 1933, as amended
(the "Securities Act") relating to the securities that may be offered by this
prospectus. This prospectus is a part of that registration statement. We have
omitted parts of the registration statement in accordance with the rules and
regulations of the SEC. For more detail about us and any securities that may be
offered by this prospectus, you may examine the registration statement on Form
S-3 and the exhibits filed with it at the locations described below under the
heading "Where You Can Find More Information."
You should rely only on the information provided or incorporated by reference in
this prospectus or any applicable prospectus supplement. We have not authorized
anyone to provide you with different or additional information. We are not
making an offer to sell these securities in any jurisdiction where the offer or
sale of these securities is not permitted. You should not assume that the
information appearing in this prospectus, any prospectus supplement, or the
documents incorporated by reference herein or therein is accurate as of any date
other than their respective dates. Our business, financial condition, results of
operations and prospects may have changed since those dates.
In this prospectus and any prospectus supplement, unless otherwise indicated,
the terms "Celgene," "we," "us" and "our" refer and relate to Celgene
Corporation and its consolidated subsidiaries.
1
PROSPECTUS SUMMARY
CELGENE CORPORATION
We are a multi-national biopharmaceutical company primarily engaged in the
discovery, development and commercialization of innovative therapies designed to
treat cancer and immune-inflammatory related diseases. Our primary commercial
products are: REVLIMID(R) (lenalidomide), which was approved by the U.S. Food
and Drug Administration, or FDA, in December 2005 for treatment of patients with
transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic
syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or
without additional cytogenetic abnormalities and in June 2006 for treatment in
combination with dexamethasone for multiple myeloma patients who have received
at least one prior therapy; and THALOMID(R) (thalidomide), which gained FDA
approval in May 2006 for treatment in combination with dexamethasone of newly
diagnosed multiple myeloma patients and which is also approved in erythema
nodosum leprosum, an inflammatory complication of leprosy. The sales growth of
REVLIMID(R) and THALOMID(R) has enabled us to make substantial investments in
research and development, which has advanced our broad portfolio of drug
candidates in our product pipeline, including a pipeline of IMiD(R) compounds,
which are proprietary to us and have demonstrated certain anti-proliferative
immunomodulatory and other biologically important properties. We believe that
the commercial potential of REVLIMID(R) and THALOMID(R), the depth of our
product pipeline, near-term regulatory activities, new disease indications,
geographic/international market expansion and clinical data reported both at
major medical conferences and in peer-reviewed publications provide the
catalysts for future growth.
We are dedicated to innovative research and development designed to bring new
therapies to market. We are involved in research in several scientific areas
that may deliver proprietary next-generation therapies, such as cellular
signaling biology, immunomodulation and placental stem cell research. The
therapies (drugs and cell therapies) we develop are designed to treat
life-threatening diseases or chronic debilitating conditions where patients are
poorly served by current therapies. Building on our growing knowledge of the
biology underlying hematological and solid tumor cancers and immune-inflammatory
diseases, we are investing in a range of innovative therapeutic programs that
are investigating ways to target or treat chronically managed diseases by
targeting multiple mechanisms at their source.
Our principal executive offices are located at 86 Morris Avenue, Summit, New
Jersey 07901, and our telephone number is (908) 673-9000. Additional information
regarding us is set forth in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2005, our Quarterly Reports on Form 10-Q for the fiscal
quarters ended March 31, 2006 and June 30, 2006 and our Current Reports on Form
8-K (which are incorporated by reference in this prospectus). See "Where You Can
Find More Information" and "Incorporation by Reference."
RECENT EVENTS
Celgene reported net income of $20.4 million, or diluted earnings per share of
$0.05 for the quarter ended September 30, 2006, including share-based employee
compensation expense, compared to net income in the prior year period of $0.7
million, or diluted earnings per share of $0.00. Total revenue was $244.8
million for the quarter ended September 30, 2006, an increase of 89.1% over the
same period in 2005 driven by REVLIMID(R) net sales of $101.3 million, aided by
conversion of expanded access patients to paying patients and $5 million to $10
million of inventory build related to the introduction of the new 15 and 25
milligram capsules. THALOMID net sales were $108.4 million, an increase of 9.3%
year-over-year. ALKERAN(R) net sales for the third quarter were $12.2 million in
2006 compared to $13.9 million in 2005. Revenue from Focalin(TM) and the
Ritalin(R) family of drugs totaled $17.9 million for the third quarter of 2006
compared to $10.7 million over the same period last year.
For the nine-month period, total net product sales were $559.7 million, an
increase of 76.6% over the same period in 2005. REVLIMID(R) sales for the
nine-month period were $196.8 million. THALOMID(R) sales for the nine-month
period of 2006 were $322.8 million compared to $282.0 million in 2005, an
increase of 14.5% year-over-year. During the nine-month period of 2006, Celgene
announced net income of $46.1 million or earnings per diluted share of $0.12,
compared to net income of $59.7 million or earnings of $0.16 per diluted share
in the first nine-months of last year.
2
Selling, general and administrative expenses were $89.6 million for the
three-month period ended September 30, 2006, representing an increase of 90.9%
compared to the year ago quarter. Selling, general and administrative expenses
during the third quarter of 2006 included $20.1 million of shared-based
compensation expense resulting from the application of Statement of Financial
Accounting Standards No. 123(R), "Share-Based Payment," effective January 1,
2006. Selling, general and administrative expenses also increased due to higher
marketing and sales expenses related to REVLIMID(R) and THALOMID(R) product
launch activities in the United States, and continued expansion of Celgene
internationally.
Celgene reported $872.5 million in cash and marketable securities as of
September 30, 2006, an increase of $148.2 million from December 31, 2005.
RISK FACTORS
Investment in the offered securities involves risks. Before acquiring any
offered securities pursuant to this prospectus, you should carefully consider
the information contained or incorporated by reference in this prospectus or in
any accompanying prospectus supplement, including, without limitation, the risks
of an investment in our company set forth below and under the captions "Item 1A.
Risk Factors" and "Item 7. Management's Discussion and Analysis of Financial
Condition and Results of Operations" in our Annual Report on Form 10-K for the
fiscal year ended December 31, 2005, Part 1, Item 2. "Management's Discussion
and Analysis of Financial Condition and Results of Operations" in our Quarterly
Reports for the fiscal quarters ended March 31, 2006 and June 30, 2006 and our
Current Reports on Form 8-K, as the same may be updated from time to time by our
future filings with the SEC. The occurrence of any of these risks might cause
you to lose all or a part of your investment in the offered securities. Please
also refer to the section below entitled "Forward-Looking Statements."
FORWARD-LOOKING STATEMENTS
Certain statements contained or incorporated by reference in this prospectus and
any accompanying prospectus supplement are forward-looking statements within the
meaning of Section 27A of the Securities Act and Section 21E of the Securities
Exchange Act of 1934, as amended (the "Exchange Act") and are included, for
example, in the discussions about:
- our strategy;
- new product discovery, development or product introduction;
- product manufacturing;
- product sales, royalties and contract revenues;
- expenses and net income;
- investment income;
- capital investments;
- clinical and regulatory activities;
- our credit risk management;
- our liquidity;
- our asset/liability risk management; and
- our operational and legal risks.
3
These and other forward-looking statements involve risks and uncertainties.
Actual results may differ materially from those expressed or implied in those
statements. You are cautioned not to unduly rely on the forward-looking
statements contained in this prospectus and any accompanying prospectus
supplement. Factors that could cause such differences include, but are not
limited to, those risks and uncertainties discussed under the caption "Item 1A.
Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2005, Part 1, Item 2. "Management's Discussion and Analysis of
Financial Condition and Results of Operations" in our Quarterly Reports for the
fiscal quarters ended March 31, 2006 and June 30, 2006 and our Current Reports
on Form 8-K, that are incorporated by reference in this prospectus.
USE OF PROCEEDS
Unless otherwise indicated in a prospectus supplement, the net proceeds from the
sale of securities offered by this prospectus will be used for general corporate
purposes, including, without limitation, further development of our clinical and
pre-clinical programs, expansion of our international operations, capital
expenditures, repayment of indebtedness and to meet working capital needs. We
expect from time to time to evaluate the acquisition of businesses, products and
technologies for which a portion of the net proceeds may be used. If net
proceeds from a specific offering will be used to repay indebtedness, the
applicable prospectus supplement will describe the relevant terms of the debt to
be repaid. We will not receive proceeds from sales of securities by persons
other than us except as may otherwise be stated in an applicable prospectus
supplement.
4
RATIO OF EARNINGS TO FIXED CHARGES
The following table shows our historical ratio of earnings to fixed charges, or
deficiency of earnings, for the six months ended June 30, 2006 and each of the
five most recent fiscal years (dollars in thousands):
FISCAL YEARS ENDED DECEMBER 31,
Six Months
Ended
June 30, 2006 2005 2004 2003 2002 2001
------------- ---- ---- ---- ---- ----
Ratio of earnings
to fixed charges (1) 15.8 10.3 7.4 6.1 -- --
Deficiency of earnings
available to cover
fixed charges (2) -- -- -- -- $(91,590) $(4,136)
(1) For purposes of computing the ratio of earnings to fixed charges,
earnings consist of the sum of our pretax income from continuing operations
before loss from equity investees and fixed charges. Fixed charges consist of
interest expense, amortization of debt discount and premium, capitalized
interest and a portion of lease payments considered to represent an interest
factor.
(2) There was a deficiency of earnings available to cover fixed charges for
the years 2001 and 2002 because we incurred net losses in each of those years.
5
DESCRIPTION OF CAPITAL STOCK
Our authorized capital stock consists of 575,000,000 shares of common stock, par
value $.01 per share, and 5,000,000 shares of preferred stock, par value $.01
per share, of which 520 shares have been designated Series A convertible
preferred stock and 20,000 shares have been designated as Series B convertible
preferred stock. As of November 1, 2006, there were 352,441,666 shares of common
stock outstanding, no shares of Series A convertible preferred stock outstanding
and no shares of Series B convertible preferred stock outstanding.
COMMON STOCK
Holders of common stock are entitled to one vote for each share held on all
matters submitted to a vote of stockholders, and do not have cumulative voting
rights. Holders of common stock are entitled to receive ratably such dividends,
if any, as may be declared by our board of directors out of funds legally
available therefor, and subject to any preferential dividend rights of any then
outstanding preferred stock. Upon our liquidation, dissolution or winding up,
the holders of common stock are entitled to receive ratably our net assets
available after the payment of all debts and other liabilities and subject to
any liquidation preference of any then outstanding preferred stock. Holders of
common stock have no preemptive, subscription or conversion rights. There are no
redemption or sinking fund provisions applicable to the common stock. The
outstanding shares of common stock are, and any shares offered by us in this
offering will be when issued and paid for, fully paid and non-assessable.
PREFERRED STOCK
Our board of directors has the authority, subject to certain restrictions,
without further stockholder approval, to issue, at any time and from time to
time, shares of preferred stock in one or more series. Each such series shall
have such number of shares, designations, preferences, voting powers,
qualifications and special or relative rights or privileges as shall be
determined by our board of directors, which may include, among others, dividend
rights, voting rights, redemption and sinking fund provisions, liquidation
preferences, conversion rights and preemptive rights, to the full extent now or
hereafter permitted by the laws of the State of Delaware.
The rights of the holders of common stock will be subject to, and may be
adversely affected by, the rights of holders of any preferred stock that may be
issued in the future. Such rights may include voting and conversion rights which
could adversely affect the holders of the common stock. Satisfaction of any
dividend or liquidation preferences of outstanding preferred stock would reduce
the amount of funds available, if any, for the payment of dividends or
liquidation amounts on common stock. Holders of preferred stock would typically
be entitled to receive a preference payment.
SHAREHOLDER RIGHTS PLAN
Our board of directors has adopted a shareholder rights plan. The shareholder
rights plan was adopted to give our board of directors increased power to
negotiate in our best interests and to discourage appropriation of control of us
at a price that is unfair to our stockholders. It is not intended to prevent
fair offers for acquisition of control determined by our board of directors to
be in the best interests of us and our stockholders, nor is it intended to
prevent a person or group from obtaining representation on or control of our
board of directors through a proxy contest, or to relieve our board of directors
of its fiduciary duty to consider any proposal for our acquisition made in good
faith.
The shareholder rights plan involves the distribution of one "right" as a
dividend on each outstanding share of our common stock to all holders of record
on September 26, 1996, and an ongoing distribution of one right with respect to
each share of our common stock issued subsequently. Each right shall entitle the
holder to purchase one-tenth of a share of common stock. The rights trade in
tandem with the common stock until, and become exercisable upon, the occurrence
of certain triggering events, and the exercise price is based on the estimated
long-term value of our common stock. The exercise of these rights becomes
economically attractive upon the triggering of certain "flip-in" or "flip-over"
rights which work in conjunction with the shareholder rights plan's basic
provisions. The flip-in rights will permit their holders to purchase shares of
common stock at a discounted rate, resulting in substantial dilution of an
acquiror's voting and economic interests in us. The flip-over element of the
shareholder rights plan involves
6
some mergers or significant asset purchases, which trigger certain rights to
purchase shares of the acquiring or surviving company at a discount. The
shareholder rights plan contains a "permitted offer" exception which allows
offers determined by our board of directors to be in our best interests and our
stockholders to take place free of the diluting effects of the shareholder
rights plan's mechanisms.
Our board of directors retains the right, at all times prior to acquisition of
15% or more of our voting common stock by an acquiror, to discontinue the
shareholder rights plan through the redemption of all rights, or to amend the
shareholder rights plan in any respect. In February, 2000, we amended the
shareholder rights plan to increase the initial exercise price thereunder from
$100 to $700. In August 2003, we amended the shareholder rights plan to provide
that a qualified institutional investor (as defined in the amendment) will not
trigger any rights under the plan until it beneficially owns at least 17% of the
shares of our outstanding common stock, rather than 15%.
DELAWARE LAW AND SOME BY-LAW PROVISIONS
Our board of directors has adopted certain amendments to our by-laws intended to
strengthen our board of directors' position in the event of a hostile takeover
attempt. These by-law provisions have the following effects:
o they provide that only persons who are nominated in accordance with the
procedures set forth in the by-laws shall be eligible for election as our
directors, except as may be otherwise provided in the by-laws;
o they provide that only business brought before the annual meeting by our
board of directors or by a stockholder who complies with the procedures set
forth in the by-laws may be transacted at an annual meeting of stockholders;
o they provide that only the chairman of the board, if any, the chief executive
officer, the president, the secretary or a majority of our board of directors
may call special meetings of our stockholders;
o they establish a procedure for our board of directors to fix the record date
whenever stockholder action by written consent is undertaken; and
o they require a vote of holders of two-thirds of the outstanding shares of
common stock to amend certain by-law provisions.
Furthermore, we are subject to the provisions of Section 203 of the Delaware
General Corporation Law, an anti-takeover law. In general, the statute prohibits
a publicly held Delaware corporation from engaging in a "business combination"
with an "interested stockholder" for a period of three years after the date of
the transaction in which the person became an interested stockholder, unless the
business combination is approved in a prescribed manner. For purposes of Section
203, a "business combination" includes a merger, asset sale or other transaction
resulting in a financial benefit to the interested stockholder, and an
"interested stockholder" is a person who, together with affiliates and
associates, owns, or within three years prior, did own, 15% or more of the
corporation's voting stock.
TRANSFER AGENT AND REGISTRAR
The transfer agent and registrar for the common stock is American Stock Transfer
& Trust Company. It is located at 59 Maiden Lane, New York, NY 10038, and its
telephone number is (718) 921-8200.
7
DESCRIPTION OF DEBT SECURITIES
This prospectus may be used for an offering of any combination of our senior
debt securities or subordinated debt securities. Debt securities, whether senior
or subordinated, may be issued as convertible debt securities or exchangeable
debt securities. Senior debt securities and subordinated debt securities will be
issued under separate indentures between us, as issuer, and The Bank of New York
as trustee. Further information regarding the trustee may be provided in the
applicable prospectus supplement. The form of each type of indenture is filed as
an exhibit to the registration statement of which this prospectus is a part. The
indentures are substantially identical except for the subordination provisions
described below under "Subordinated Debt Securities." Particular debt securities
will be issued in one or more series, the terms of which will be part of a
supplemental indenture that will be filed by us with the SEC in connection with
a particular offering. Where we refer to either indenture below, we mean the
indenture as well as any applicable supplemental indenture.
The applicable prospectus supplement will describe the particular terms of any
debt securities that may be offered and may supplement the terms summarized
below. The following summaries of the debt securities and the indentures are not
complete. We urge you to read the indentures filed as exhibits to the
registration statement which includes this prospectus and the description of the
additional terms of the debt securities included in the applicable prospectus
supplement. All capitalized terms in the following summaries have the meanings
specified in the indentures.
GENERAL
Debt securities may be issued in separate series without limitation as to
aggregate principal amount. We may specify a maximum aggregate principal amount
for the debt securities of any series.
We are not limited as to the amount of debt securities we may issue under the
indentures. The prospectus supplement will set forth:
- whether the debt securities will be senior or subordinated,
- the offering price,
- the title,
- any limit on the aggregate principal amount,
- the person who shall be entitled to receive interest, if other than the
record holder on the record date,
- the date the principal will be payable,
- the interest rate, if any, the date interest will accrue, the interest
payment dates and the regular record dates,
- the place where payments may be made,
- any mandatory or optional redemption provisions,
- any obligation to redeem or purchase the debt securities pursuant to a
sinking fund,
- if applicable, the method for determining how the principal, premium, if
any, or interest will be calculated by reference to an index or formula,
- conversion or exchange provisions, if any, including conversion or
exchange prices or rates and adjustments thereto,
8
- if other than U.S. currency, the currency or currency units in which
principal, premium, if any, or interest will be payable and whether we or
the holder may elect payment to be made in a different currency,
- the portion of the principal amount that will be payable upon acceleration
of stated maturity, if other than the entire principal amount,
- if the principal amount payable at stated maturity will not be
determinable as of any date prior to stated maturity, the amount which
will be deemed to be the principal amount,
- any defeasance provisions if different from those described below under
"Satisfaction and Discharge; Defeasance,"
- any conversion or exchange provisions,
- whether the debt securities will be issuable in the form of a global
security,
- any subordination provisions, if different than those described below
under "Subordinated Debt Securities,"
- any deletions of, or changes or additions to, the events of default or
covenants, and
- any other specific terms of such debt securities.
Unless otherwise specified in a prospectus supplement:
- the debt securities will be registered debt securities, and
- registered debt securities denominated in U.S. dollars will be issued in
denominations of $1,000 or an integral multiple of $1,000.
Debt securities may be sold at a substantial discount below their stated
principal amount, bearing no interest or interest at a rate which at time of
issuance is below market rates.
EXCHANGE AND TRANSFER
Debt securities may be transferred or exchanged at the office of the security
registrar or at the office of any transfer agent designated by us.
We will not impose a service charge for any transfer or exchange, but we may
require holders to pay any tax or other governmental charges associated with any
transfer or exchange.
In the event of any potential redemption of debt securities of any series, we
will not be required to:
- issue, register the transfer of, or exchange, any debt security of that
series during a period beginning at the opening of business 15 days before
the day of mailing of a notice of redemption and ending at the close of
business on the day of the mailing, or
- register the transfer of or exchange any debt security of that series
selected for redemption, in whole or in part, except the unredeemed
portion being redeemed in part.
We may initially appoint the trustee as the security registrar. Any transfer
agent, in addition to the security registrar, initially designated by us will be
named in a prospectus supplement. We may designate additional transfer agents or
change transfer agents or change the office of the transfer agent. However, we
will be required to maintain a transfer agent in each place of payment for the
debt securities of each series.
9
GLOBAL SECURITIES
The debt securities of any series may be represented, in whole or in part, by
one or more global securities. Each global security will:
- be registered in the name of a depositary that we will identify in a
prospectus supplement,
- be deposited with the depositary or nominee or custodian, and
- bear any required legends.
No global security may be exchanged in whole or in part for debt securities
registered in the name of any person other than the depositary or any nominee
unless:
- the depositary has notified us that it is unwilling or unable to continue
as depositary or has ceased to be qualified to act as depositary,
- an event of default is continuing, or
- any other circumstances described in a prospectus supplement.
As long as the depositary, or its nominee, is the registered owner of a global
security, the depositary or nominee will be considered the sole owner and holder
of the debt securities represented by the global security for all purposes under
the indenture. Except in the above limited circumstances, owners of beneficial
interests in a global security:
- will not be entitled to have the debt securities registered in their
names,
- will not be entitled to physical delivery of certificated debt securities,
and
- will not be considered to be holders of those debt securities under the
indentures.
Payments on a global security will be made to the depositary or its nominee as
the holder of the global security. Some jurisdictions have laws that require
that certain purchasers of securities take physical delivery of such securities
in definitive form. These laws may impair the ability to transfer beneficial
interests in a global security.
Institutions that have accounts with the depositary or its nominee are referred
to as "participants." Ownership of beneficial interests in a global security
will be limited to participants and to persons that may hold beneficial
interests through participants. The depositary will credit, on its book-entry
registration and transfer system, the respective principal amounts of debt
securities represented by the global security to the accounts of its
participants.
Ownership of beneficial interests in a global security will be shown on and
effected through records maintained by the depositary, with respect to
participants' interests, or any participant, with respect to interests of
persons held by participants on their behalf.
Payments, transfers and exchanges relating to beneficial interests in a global
security will be subject to policies and procedures of the depositary.
The depositary policies and procedures may change from time to time. Neither we
nor the trustee will have any responsibility or liability for the depositary's
or any participant's records with respect to beneficial interests in a global
security.
PAYMENT AND PAYING AGENTS
The provisions of this paragraph will apply to the debt securities unless
otherwise indicated in a prospectus supplement. Payment of interest on a debt
security on any interest payment date will be made to the person in whose
10
name the debt security is registered at the close of business on the regular
record date. Payment on debt securities of a particular series will be payable
at the office of a paying agent or paying agents designated by us. However, at
our option, we may pay interest by mailing a check to the record holder. The
corporate trust office will be designated as our sole paying agent.
We may also name any other paying agents in a prospectus supplement. We may
designate additional paying agents, change paying agents or change the office of
any paying agent. However, we will be required to maintain a paying agent in
each place of payment for the debt securities of a particular series.
All moneys paid by us to a paying agent for payment on any debt security which
remain unclaimed at the end of two years after such payment was due will be
repaid to us. Thereafter, the holder may look only to us for such payment.
REDEMPTION
We may reserve the right to redeem and pay, or may covenant to redeem and pay,
the debt securities of any series or any part thereof prior to the stated
maturity at such time and on such terms as provided for in the debt securities.
The provisions described herein will apply to any optional and mandatory
redemption of debt securities unless otherwise indicated in a prospectus
supplement.
If less than all of the debt securities of a series are to be redeemed, the
trustee will select the securities of the series to be redeemed in a manner that
the trustee deems fair and appropriate, in denominations larger than $1,000. We
will mail a notice of redemption at least 30 days but not more than 60 days
before the redemption date by first-class mail to each holder whose debt
securities are to be redeemed. The notice will identify the debt securities to
be redeemed and will state:
- the redemption date;
- the redemption price;
- the name and address of the paying agent;
- that the debt securities called for redemption must be surrendered to the
paying agent to collect the redemption price;
- that interest on the debt securities called for redemption ceases to
accrue on and after the redemption date; and
- any other required information.
Once the notice of redemption is mailed, the debt securities called for
redemption will become due and payable on the redemption date at the redemption
price. The paying agent will pay the redemption price plus accrued interest to
the redemption date to the holder of the redeemed debt securities upon surrender
of such debt securities.
CONSOLIDATION, MERGER AND SALE OF ASSETS
We may not consolidate with or merge into any other person, in a transaction in
which we are not the surviving corporation, or convey, transfer or lease our
properties and assets substantially as an entirety to, any person, unless:
- the successor, if any, is a U.S. corporation, limited liability company,
partnership, trust or other entity,
- the successor assumes our obligations on the debt securities and under the
indenture,
- immediately after giving effect to the transaction, no default or event of
default shall have occurred and be continuing, and
- certain other conditions are met.
11
EVENTS OF DEFAULT
Unless we inform you otherwise in a prospectus supplement, the indenture will
define an event of default with respect to any series of debt securities as one
or more of the following events:
(1) failure to pay principal of or any premium on any debt security of that
series when due,
(2) failure to pay any interest on any debt security of that series for 30
days when due,
(3) failure to deposit any sinking fund payment when due,
(4) failure to perform any other covenant in the indenture continued for 60
days after being given the notice required in the indenture,
(5) our bankruptcy, insolvency or reorganization, and
(6) any other event of default specified in a prospectus supplement.
An event of default of one series of debt securities is not necessarily an event
of default for any other series of debt securities. If an event of default,
other than an event of default described in clause (5) above, shall occur and be
continuing, either the trustee or the holders of at least 25% in aggregate
principal amount of the outstanding securities of that series may declare the
principal amount of the debt securities of that series to be due and payable
immediately.
If an event of default described in clause (5) above shall occur, the principal
amount of all the debt securities of that series will automatically become
immediately due and payable. Any payment by us on the subordinated debt
securities following any such acceleration will be subject to the subordination
provisions described below under "Subordinated Debt Securities."
After acceleration the holders of a majority in aggregate principal amount of
the outstanding securities of that series may, under certain circumstances,
rescind and annul such acceleration if all events of default, other than the
non-payment of accelerated principal, or other specified amount, have been cured
or waived.
Other than the duty to act with the required care during an event of default,
the trustee will not be obligated to exercise any of its rights or powers at the
request of the holders unless the holders shall have offered to the trustee
reasonable indemnity. Generally, the holders of a majority in aggregate
principal amount of the outstanding debt securities of any series will have the
right to direct the time, method and place of conducting any proceeding for any
remedy available to the trustee or exercising any trust or power conferred on
the trustee.
A holder will not have any right to institute any proceeding under the
indentures, or for the appointment of a receiver or a trustee, or for any other
remedy under the indentures, unless:
(1) the holder has previously given to the trustee written notice of a
continuing event of default with respect to the debt securities of that
series,
(2) the holders of at least 25% in aggregate principal amount of the
outstanding debt securities of that series have made a written request and
have offered reasonable indemnity to the trustee to institute the
proceeding, and
(3) the trustee has failed to institute the proceeding and has not received
direction inconsistent with the original request from the holders of a
majority in aggregate principal amount of the outstanding debt securities
of that series within 60 days after the original request.
12
Holders may, however, sue to enforce the payment of principal, premium or
interest on any debt security on or after the due date or to enforce the right,
if any, to convert any debt security without following the procedures listed in
(1) through (3) above.
We will furnish the trustee an annual statement by our officers as to whether or
not we are in default in the performance of the indenture and, if so, specifying
all known defaults.
MODIFICATION AND WAIVER
We and the trustee may make modifications and amendments to the indentures with
the consent of the holders of a majority in aggregate principal amount of the
outstanding securities of each series affected by the modification or amendment.
However, neither we nor the trustee may make any modification or amendment
without the consent of the holder of each outstanding security of that series
affected by the modification or amendment if such modification or amendment
would:
- change the stated maturity of any debt security,
- reduce the principal, premium, if any, or interest on any debt security,
- reduce the principal of an original issue discount security or any other
debt security payable on acceleration of maturity,
- reduce the rate of interest on any debt security,
- change the currency in which any debt security is payable,
- impair the right to enforce any payment after the stated maturity or
redemption date,
- waive any default or event of default in payment of the principal of,
premium or interest on any debt security,
- waive a redemption payment or modify any of the redemption provisions of
any debt security,
- adversely affect the right to convert any debt security, or
- change the provisions in the indenture that relate to modifying or
amending the indenture.
SATISFACTION AND DISCHARGE; DEFEASANCE
We may be discharged from our obligations on the debt securities of any series
that have matured or will mature or be redeemed within one year if we deposit
with the trustee enough cash to pay all the principal, interest and any premium
due to the stated maturity date or redemption date of the debt securities.
Each indenture contains a provision that permits us to elect:
- to be discharged from all of our obligations, subject to limited
exceptions, with respect to any series of debt securities then
outstanding, and/or
- to be released from our obligations under the following covenants and from
the consequences of an event of default resulting from a breach of these
covenants:
(1) the subordination provisions under the subordinated indenture, and
(2) covenants as to payment of taxes and maintenance of corporate
existence.
13
To make either of the above elections, we must deposit in trust with the trustee
enough money to pay in full the principal, interest and premium on the debt
securities. This amount may be made in cash and/or U.S. government obligations.
As a condition to either of the above elections, we must deliver to the trustee
an opinion of counsel that the holders of the debt securities will not recognize
income, gain or loss for Federal income tax purposes as a result of the action.
If any of the above events occurs, the holders of the debt securities of the
series will not be entitled to the benefits of the indenture, except for the
rights of holders to receive payments on debt securities or the registration of
transfer and exchange of debt securities and replacement of lost, stolen or
mutilated debt securities.
NOTICES
Notices to holders will be given by mail to the addresses of the holders in the
security register.
GOVERNING LAW
The indentures and the debt securities will be governed by, and construed under,
the law of the State of New York.
REGARDING THE TRUSTEE
The indenture limits the right of the trustee, should it become a creditor of
us, to obtain payment of claims or secure its claims.
The trustee is permitted to engage in certain other transactions. However, if
the trustee acquires any conflicting interest, and there is a default under the
debt securities of any series for which they are trustee, the trustee must
eliminate the conflict or resign.
SUBORDINATED DEBT SECURITIES
Payment on the subordinated debt securities will, to the extent provided in the
indenture, be subordinated in right of payment to the prior payment in full of
all our senior indebtedness.
Upon any distribution of our assets upon any dissolution, winding up,
liquidation or reorganization, the payment of the principal of and interest on
the subordinated debt securities will be subordinated in right of payment to the
prior payment in full in cash or other payment satisfactory to the holders of
senior indebtedness of all senior indebtedness. In the event of any acceleration
of the subordinated debt securities because of an event of default, the holders
of any senior indebtedness would be entitled to payment in full in cash or other
payment satisfactory to such holders of all senior indebtedness obligations
before the holders of the subordinated debt securities are entitled to receive
any payment or distribution. The indenture requires us or the trustee to
promptly notify holders of designated senior indebtedness if payment of the
subordinated debt securities is accelerated because of an event of default.
We may not make any payment on the subordinated debt securities, including upon
redemption at the option of the holder of any subordinated debt securities or at
our option, if:
- a default in the payment of the principal, premium, if any, interest, rent
or other obligations in respect of designated senior indebtedness occurs
and is continuing beyond any applicable period of grace (called a "payment
default"), or
- a default other than a payment default on any designated senior
indebtedness occurs and is continuing that permits holders of designated
senior indebtedness to accelerate its maturity, and the trustee receives a
notice of such default (called a "payment blockage notice") from us or any
other person permitted to give such notice under the indenture (called a
"non-payment default").
We may resume payments and distributions on the subordinated debt securities:
14
- in the case of a payment default, upon the date on which such default is
cured or waived or ceases to exist, and
- in the case of a non-payment default, the earlier of the date on which
such nonpayment default is cured or waived or ceases to exist and 179 days
after the date on which the payment blockage notice is received by the
trustee, if the maturity of the designated senior indebtedness has not
been accelerated.
No new period of payment blockage may be commenced pursuant to a payment
blockage notice unless 365 days have elapsed since the initial effectiveness of
the immediately prior payment blockage notice and all scheduled payments of
principal, premium and interest, including any liquidated damages, on the debt
securities that have come due have been paid in full in cash. No non-payment
default that existed or was continuing on the date of delivery of any payment
blockage notice shall be the basis for any later payment blockage notice unless
the non-payment default is based upon facts or events arising after the date of
delivery of such payment blockage notice.
If the trustee or any holder of the notes receives any payment or distribution
of our assets in contravention of the subordination provisions on the
subordinated debt securities before all senior indebtedness is paid in full in
cash, property or securities, including by way of set-off, or other payment
satisfactory to holders of senior indebtedness, then such payment or
distribution will be held in trust for the benefit of holders of senior
indebtedness or their representatives to the extent necessary to make payment in
full in cash or payment satisfactory to the holders of senior indebtedness of
all unpaid senior indebtedness.
In the event of our bankruptcy, dissolution or reorganization, holders of senior
indebtedness may receive more, ratably, and holders of the subordinated debt
securities may receive less, ratably, than our other creditors (including our
trade creditors). This subordination will not prevent the occurrence of any
event of default under the indenture.
As of the date of this prospectus, no senior indebtedness was outstanding. We
are not prohibited from incurring debt, including senior indebtedness, under the
indenture. We may from time to time incur additional debt, including senior
indebtedness.
We are obligated to pay reasonable compensation to the trustee and to indemnify
the trustee against certain losses, liabilities or expenses incurred by the
trustee in connection with its duties relating to the subordinated debt
securities. The trustee's claims for these payments will generally be senior to
those of noteholders in respect of all funds collected or held by the trustee.
CONVERSION OR EXCHANGE RIGHTS
Debt securities may be convertible into or exchangeable for shares of our common
stock. The terms and conditions of conversion or exchange will be stated in the
applicable prospectus supplement. The terms will include, among others, the
following:
- the conversion or exchange price,
- the conversion or exchange period,
- provisions regarding the convertibility or exchangeability of the debt
securities, including who may convert or exchange,
- events requiring adjustment to the conversion or exchange price,
- provisions affecting conversion or exchange in the event of our redemption
of the debt securities, and
- any anti-dilution provisions, if applicable.
15
NO INDIVIDUAL LIABILITY OF STOCKHOLDERS, OFFICERS OR DIRECTORS
The indentures provide that none of our past, present or future stockholders,
officers or directors, or stockholders, officers or directors of any successor
corporation, in their capacity as such shall have any individual liability for
any of our obligations, covenants or agreements under the debt securities or the
applicable indenture.
NO CHANGE IN CONTROL PUT OPTIONS
The indentures do not provide that debt securities may be put to us at the
option of the debtholder in the event of a change in control, highly leveraged
transaction or other events. If we decide subsequently to provide such put
options, an appropriate disclosure will be provided by prospectus supplement,
including whether we maintain other indebtedness with similar features and the
potential difficulties, if any, in meeting such simultaneous obligations.
NO SECURED INDEBTEDNESS
As of the date of this prospectus, we have no secured indebtedness, and none of
our subsidiaries have any outstanding indebtedness. An appropriate disclosure
will be provided by prospectus supplement to disclose any subsequent change in
the foregoing.
PLAN OF DISTRIBUTION
We or any selling securityholder may offer and sell the offered securities on a
delayed or continuous basis through agents, underwriters or dealers, directly to
one or more purchasers, through a combination of any of these methods of sale,
or in any other manner, as provided in the applicable prospectus supplement.
We may sell the securities offered pursuant to this prospectus and any
accompanying prospectus supplements to or through one or more underwriters or
dealers or we may sell the securities to investors directly or through agents.
Each prospectus supplement, to the extent applicable, will describe the number
and terms of the securities to which such prospectus supplement relates, the
name or names of any underwriters or agents with whom we have entered into
arrangements with respect to the sale of such securities, the public offering or
purchase price of such securities and the net proceeds we will receive from such
sale. Any underwriter or agent involved in the offer and sale of the securities
will be named in the applicable prospectus supplement. We may sell securities
directly to investors on our own behalf in those jurisdictions where we are
authorized to do so.
Underwriters may offer and sell the securities at a fixed price or prices, which
may be changed, at market prices prevailing at the time of sale, at prices
related to the prevailing market prices or at negotiated prices. We also may,
from time to time, authorize dealers or agents to offer and sell these
securities upon such terms and conditions as may be set forth in the applicable
prospectus supplement. In connection with the sale of any of these securities,
underwriters may receive compensation from us in the form of underwriting
discounts or commissions and may also receive commissions from purchasers of the
securities for whom they may act as agent. Underwriters may sell the securities
to or through dealers, and such dealers may receive compensation in the form of
discounts, concessions or commissions from the underwriters or commissions from
the purchasers for which they may act as agents.
Shares may also be sold in one or more of the following transactions: (a) block
transactions (which may involve crosses) in which a broker-dealer may sell all
or a portion of the shares as agent but may position and resell all or a portion
of the block as principal to facilitate the transaction; (b) purchases by a
broker-dealer as principal and resale by the broker-dealer for its own account
pursuant to a prospectus supplement; (c) a special offering, an exchange
distribution or a secondary distribution in accordance with applicable stock
exchange rules; (d) ordinary brokerage transactions and transactions in which a
broker-dealer solicits purchasers; (e) sales "at the market" to or through a
market maker or into an existing trading market, on an exchange or otherwise,
for shares; and (f) sales in other ways not involving market makers or
established trading markets, including direct sales to purchasers.
Broker-dealers may also receive compensation from purchasers of the shares which
is not expected to exceed that customary in the types of transactions involved.
Any underwriting compensation paid by us to underwriters or agents in connection
with the offering of these securities, and any discounts or concessions or
commissions allowed by underwriters to participating dealers, will be set forth
in the applicable prospectus supplement. Dealers and agents participating in the
distribution of the securities may be deemed to be underwriters, and any
discounts and commissions received by them and any profit realized by them on
resale of the securities may be deemed to be underwriting discounts and
commissions.
Underwriters, dealers and agents may be entitled, under agreements entered into
with us, to indemnification against and contribution toward certain civil
liabilities, including liabilities under the Securities Act of 1933. Unless
otherwise set forth in the accompanying prospectus supplement, the obligations
of any underwriters to purchase any of these securities will be subject to
certain conditions precedent.
In connection with the offering of the securities hereby, certain underwriters,
and selling group members and their respective affiliates, may engage in
transactions that stabilize, maintain or otherwise affect the market price of
the applicable securities. These transactions may include stabilization
transactions effected in accordance with Rule 104 of Regulation M promulgated by
the SEC pursuant to which these persons may bid for or purchase securities for
the purpose of stabilizing their market price.
The underwriters in an offering of securities may also create a "short position"
for their account by selling more securities in connection with the offering
than they are committed to purchase from us. In that case, the underwriters
could cover all or a portion of the short position by either purchasing
securities in the open market following completion of the offering of these
securities or by exercising any over-allotment option granted to them by us. In
addition, the managing underwriter may impose "penalty bids" under contractual
arrangements with other underwriters, which means that they can reclaim from an
underwriter (or any selling group member participating in the offering) for the
account of the other underwriters, the selling concession for the securities
that are distributed in the offering but subsequently purchased for the account
of the underwriters in the open market. Any of the transactions described in
this paragraph or comparable transactions that are described in any accompanying
prospectus supplement may result in the maintenance of the price of the
securities at a level above that which might otherwise prevail in the open
market. None of the transactions described in this paragraph or in an
accompanying prospectus supplement are required to be taken by any underwriters
and, if they are undertaken, may be discontinued at any time.
Any underwriters or agents to or through which securities are sold by us may
make a market in the securities, but these underwriters or agents will not be
obligated to do so and any of them may discontinue any market making at any time
without notice. No assurance can be given as to the liquidity of or trading
market for any securities sold by us.
Any lockup arrangements will be set forth in a prospectus supplement.
Underwriters, dealers and agents may engage in transactions with, or perform
services for, us and our affiliates in the ordinary course of business.
Underwriters have from time to time in the past provided, and may from time to
time in the future provide, investment banking services to us for which they
have in the past received, and may in the future receive, customary fees.
LEGAL MATTERS
In connection with particular offerings of the securities in the future, and if
stated in the applicable prospectus supplements, the validity of those
securities may be passed upon for Celgene Corporation by Proskauer Rose LLP, New
York, New York and for any underwriters or agents by counsel named in the
applicable prospectus supplement.
EXPERTS
The consolidated financial statements and schedule of Celgene Corporation and
subsidiaries as of December 31, 2005 and 2004, and for each of the years in the
three-year period ended December 31, 2005, and management's assessment of the
effectiveness of internal control over financial reporting as of December 31,
2005 have been incorporated by reference herein and in the registration
statement in reliance upon the reports of KPMG LLP, independent registered
public accounting firm, incorporated by reference herein, and upon the authority
of said firm as experts in accounting and auditing.
The statements that relate to U.S. patent rights licensed from The Rockefeller
University and Children's Medical Center Corporation under the caption "Item 1A.
Risk Factors--We may not be able to protect our intellectual property and our
products may be subject to generic competition" in our Annual Report on Form
10-K for the fiscal year ended December 31, 2005, and that have been
incorporated by reference herein this prospectus, have been reviewed and
approved by Jones Day LLP as our special patent counsel for these matters, and
are included herein in reliance upon their review and approval as our patent
counsel.
16
With the exception of the statements regarding stem cell related activities, the
statements describing legal and regulatory requirements under the caption "Item
1A. Risk Factors-The pharmaceutical industry is subject to extensive government
regulation which presents numerous risks to us" in our Annual Report on Form
10-K for the fiscal year ended December 31, 2005, and that have been
incorporated by reference in this prospectus, have been reviewed and, assuming
the accuracy of the factual statements made, approved by Kleinfeld, Kaplan &
Becker, as experts in such matters, and are included herein in reliance upon
such review and approval.
The statements that relate to trademarks under the caption "Item 1A. Risk
Factors--We may not be able to protect our intellectual property and our
products may be subject to generic competition" in our Annual Report on Form
10-K for the fiscal year ended December 31, 2005, and that have been
incorporated by reference in this prospectus, have been reviewed by Cozen
O'Connor as our special trademarks counsel for these matters and are included
herein in reliance upon such review and approval.
WHERE YOU CAN FIND MORE INFORMATION
We are required to file annual, quarterly and current reports, proxy statements
and other information with the SEC. You may read and copy any document that we
file with the SEC at the SEC's Public Reference Room at 100 F Street, N.E.,
Washington, D.C. 20549. You may obtain information about the Public Reference
Room by calling the SEC for more information at 1-800-SEC-0330. Our SEC filings
are also available at the SEC's web site at http://www.sec.gov.
Our common stock is listed on the NASDAQ Global Select Market under the symbol
"CELG"and we are required to file reports, proxy statements and other
information with NASDAQ. You may read any document we file with NASDAQ at the
offices of the NASDAQ Stock Market, Inc. For further information about obtaining
copies of our public filings from the NASDAQ Global Select Market, please call
(212) 401-8700.
17
INCORPORATION BY REFERENCE
The SEC's rules allow us to "incorporate by reference" the information we file
with them, which means that we can disclose important information to you by
referring you to those documents. The information incorporated by reference is
considered to be part of this prospectus, and information that we file later
with the SEC will automatically update and, where applicable, supersede any
information.
We incorporate by reference into this prospectus the following documents or
information filed with the SEC (other than, in each case, documents or
information deemed to have been furnished and not filed in accordance with SEC
rules):
1. Our Annual Report on Form 10-K for the fiscal year ended December 31,
2005;
2. Our Quarterly Reports on Form 10-Q for fiscal quarters ended March 31,
2006 and June 30, 2006;
3. Our Current Reports on Form 8-K filed with the SEC on January 3, 2006,
January 20, 2006, February 21, 2006, April 20, 2006, May 3, 2006, May 26,
2006, June 23, 2006, June 30, 2006 and November 3, 2006.
4. The description of our common stock contained in our Registration
Statement on Form 8-A, File No. 0-16132, including any amendment or report
filed for the purpose of updating such description;
5. All documents filed by us with the SEC pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act on or after the date of this prospectus
and prior to the termination of the offering.
You may request a copy of these filings, at no cost, by writing or telephoning
our Secretary at the following address:
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
(908) 673-9000
18
================================================================================
20,000,000 SHARES
[CELGENE LOGO]
CELGENE CORPORATION
COMMON STOCK
---------------------
PROSPECTUS SUPPLEMENT
---------------------
JPMORGAN
MERRILL LYNCH & CO.
------------
BEAR, STEARNS & CO. INC.
CITIGROUP
GOLDMAN, SACHS & CO.
MORGAN STANLEY
------------
FRIEDMAN BILLINGS RAMSEY
JMP SECURITIES
LAZARD CAPITAL MARKETS
LEERINK SWANN & COMPANY
PIPER JAFFRAY
RODMAN & RENSHAW
THOMAS WEISEL PARTNERS LLC
NOVEMBER 3, 2006
================================================================================